Lotiglipron is a GLP-1 receptor agonist that was tested against semaglutide, the active ingredient of Novo Nordisk’s Ozempic and Wegovy. Among the study participants who experienced elevated liver enzymes, none saw related side effects, “there was no evidence of liver failure and none needed treatment,” Pfizer said in a news release.
Transaminitis is not a disease but can be a clue other issues — such as alcohol-related and non-alcohol-related fatty liver disease — exist.
The company said it will continue researching danuglipron, another GLP-1 receptor agonist that is in a phase 2 study for obesity and Type 2 diabetes mellitus. No transaminase events have been reported in this drug’s trials, the release said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.